Showing 5201-5210 of 6636 results for "".
- Industry Vet Curtis Cluff Named President and CFO of BioPhotas Inc.https://practicaldermatology.com/news/industry-vet-curtis-cluff-named-president-and-cfo-of-biophotas-inc/2461378/Curtis Cluff is the new President and Chief Financial Officer BioPhotas Inc., manufacturers of the Celluma series of light therapy devices. In this newly created role, Mr. Cluff will report to Patrick Johnson, Chief Executive Officer and inventor of the Celluma. &quo
- Study: Galderma's RelabotulinumtoxinA Earns High Marks from Patientshttps://practicaldermatology.com/news/study-galdermas-relabotulinumtoxina-earns-high-marks-from-patients/2461377/Galderma's investigational ready-to-use liquid botulinum toxin RelabotulinumtoxinA scored high patient satisfaction and psychological well-being ratings for the treatment of glabellar lines and lateral canthal lines in addition to previously reported safety and efficacy, according to pre
- Galderma Debuts Sensitive Skincare Facultyhttps://practicaldermatology.com/news/galderma-debuts-sensitive-skincare-faculty/2461372/Reinforcing its commitment to advancing dermatology for every skin story, Galderma has formed a global Sensitive Skincare Faculty, which will focus its efforts on helping people with sensitive skin live better lives. The Faculty will focus on three key pillars of research, innovation, and engagem
- Candesant Biomedical Introduces New SweatTech Initiative at ASDShttps://practicaldermatology.com/news/candesant-biomedical-novel-investigational-technology-for-hyperhydrosis/2461371/Candesant Biomedical is introducing a new initiative – SweatTech™ – at the ASDS annual meeting. The company is also developing a new novel technology (currently under FDA review) that reduces axillary hyperhidrosis. Their “TAT” (targeted alkali thermolysis) pat
- Business News: Incyte Buys Startup Villarishttps://practicaldermatology.com/news/business-news-incyte-buys-startup-villaris/2461370/Incyte will pay $70 million upfront to buy Villaris Therapeutics, a startup working on an experimental drug for vitiligo. Villaris’ lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in 2023. Villaris&
- BeautyHealth Introduces Hydrafacial x JLo Beauty Boosterhttps://practicaldermatology.com/news/beautyhealth-introduces-the-hydrafacial-x-jlo-beauty-booster/2461369/The BeautyHealth Company is rolling out the Hydrafacial x JLo Beauty Booster . “I'm so excited to partner with Hydrafacial to create the new JLo Beauty Booster,” says founder of JLo Beauty Jennifer Lopez in a news release. “Hydrafacial is one of my favorite treatme
- DermTech Presents on Value of Decentralization of Clinical Trialshttps://practicaldermatology.com/news/dermtech-presents-on-value-of-decentralization-of-clinical-trials/2461368/Technology can help decentralize clinical trials, leading to greater patient satisfaction, a more diverse patient population, better retention and cost savings, according to a presentation by DermTech at Outsourcing in Clinical Trials Southern California, held from Sept. 28-29 in San Di
- New Research: Ticks Weaken Skin's Immune Responsehttps://practicaldermatology.com/news/new-research-ticks-weaken-skins-immune-response/2461364/Tick saliva inhibits the skin's defense function, thereby increasing the risk of diseases such as tick-borne encephalitis (TBE) or Lyme disease, according to new research in the Journal of Clinical Investigation. The re
- Johnson & Johnson Announces Kenvue as the Name for New Consumer Health Companyhttps://practicaldermatology.com/news/johnson-johnson-announces-kenvue-as-the-name-for-new-consumer-health-company/2461363/Johnson & Johnson’s planned new consumer health company will be named...Kenvue. Kenvue (pronounced ken·view), is inspired by two powerful ideas: “ken” – meaning knowledge, an English word primarily used in Scotland, and “vue,” ref
- Two New Studies Highlight the Efficacy and Safety Profile of Revance's DAXXIFYhttps://practicaldermatology.com/news/two-new-studies-highlights-the-efficacy-and-safety-profile-of-daxxify/2461360/Glabellar injection of DAXXIFY show a positive effect on eyebrow position and a high response rate and duration of effect ≥24 weeks across all age and race subgroups, according to two new studies in the Aesthetic Surgery Journal. “The newly released pu